Genetics in Medicine · 2020 · 46 citations · 12 references
Life SciencesGeneticsUrologyGenitourinary OncologyHuman GeneticsMedical GeneticsGenetic Risk AssessmentGermline Cancer PredispositionGermline Cancer SusceptibilityHereditary Cancer SyndromesHereditary Urologic Cancer SyndromesProstate CancerClinical Genetic DiagnosisGenetic Predisposition To CancerGenetic Susceptibility To Prostate CancerGenetic TestingHereditary Cancer RiskHereditary Prostate CancerPathogenic Variant DetectionProstate Cancer Diagnosis
PURPOSE: We describe the pathogenic variant spectrum and identify predictors of positive results among men referred for clinical genetic testing for prostate cancer. METHODS: One thousand eight hundred twelve men with prostate cancer underwent clinical multigene panel testing between April 2012 and September 2017. Stepwise logistic regression determined the most reliable predictors of positive results among clinical variables reported on test requisition forms. RESULTS: A yield of 9.4-12.1% was observed among men with no prior genetic testing. In this group, the positive rate of BRCA1 and BRCA2 was 4.6%; the positive rate for the mismatch repair genes was 2.8%. Increasing Gleason score (odds ratio [OR] 1.19; 95% confidence interval [CI] 0.97-1.45); personal history of breast or pancreatic cancer (OR 3.62; 95% CI 1.37-9.46); family history of breast, ovarian, or pancreatic cancer (OR 2.32 95% CI 1.48-3.65); and family history of Lynch syndrome-associated cancers (OR 1.97; 95% CI 1.23-3.15) were predictors of positive results. CONCLUSION: These results support multigene panel testing as the primary genetic testing approach for hereditary prostate cancer and are supportive of recommendations for consideration of germline testing in men with prostate cancer. Expanding the criteria for genetic testing should be considered as many pathogenic variants are actionable for treatment of advanced prostate cancer.
12
Sue Richards, Nazneen Aziz, Sherri J. Bale et al. · Genetics in Medicine · 2015 · 32.2K citations · Full text
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · New England Journal of Medicine · 2015 · 2.2K citations · Full text
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Colin C. Pritchard, Joaquı́n Mateo, Michael F. Walsh et al. · New England Journal of Medicine · 2016 · 1.7K citations · Full text
Life Sciences, Genetics, Oncology +17
Early Detection of Prostate Cancer: AUA Guideline
H. Ballentine Carter, Peter C. Albertsen, Michael J. Barry et al. · The Journal of Urology · 2013 · 1.3K citations · Full text